OncoMatch/Lung Cancer — Small Cell (SCLC)/BRCA2

Lung Cancer — Small Cell (SCLC)BRCA2 Clinical Trials

BRCA2 alterations occur in a small subset of SCLC and represent a potential marker of PARP inhibitor sensitivity through homologous recombination deficiency. PARP inhibitors have shown preclinical activity in BRCA2-deficient SCLC models. Trials study PARP inhibitor combinations and maintenance strategies in HRD-selected extensive-stage SCLC including BRCA2-mutant cases.